Contents

Search

asundexian

Mechanism of action: - activated factor XI inhibitor, factor XIa inhibitor Clinical trials: - among patients with atrial fibrillation at risk for stroke, asundexian 50 mg PO QD was associated with a higher incidence of stroke or systemic embolism than apixaban with 155 day prior to prematurely stopping the trial - fewer major bleeding events occurred with asundexian than with apixaban

Interactions

drug adverse effects of direct oral anticoagulants

General

direct oral anticoagulant; novel oral anticoagulant (DOAC, NOAC)

References

  1. Piccini JP, Patel MR, Steffel J, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2024 Sep 1 PMID: 39225267 https://www.nejm.org/doi/10.1056/NEJMoa2407105